guest ::
| Home > Publications database > Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice. > print |
| Home > Publications database > Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice. > print |
| 001 | 274204 | ||
| 005 | 20240229154928.0 | ||
| 024 | 7 | _ | |a 10.3390/pathogens12020188 |2 doi |
| 024 | 7 | _ | |a pmid:36839460 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9958775 |2 pmc |
| 024 | 7 | _ | |a altmetric:142612281 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00490 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Schifflers, Christoph |0 P:(DE-He78)72642b84997c1dedbf3e62dd57dede80 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice. |
| 260 | _ | _ | |a Basel |c 2023 |b MDPI |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1678869179_29494 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F130#LA:F130# |
| 520 | _ | _ | |a Head and neck squamous cell carcinomas (HNSCC) caused by infections with high-risk human papillomaviruses (HPV) are responsible for an increasing number of head and neck cancers, particularly in the oropharynx. Despite the significant biological differences between HPV-driven and HPV-negative HNSCC, treatment strategies are similar and not HPV targeted. HPV-driven HNSCC are known to be more sensitive to treatment, particularly to radiotherapy, which is at least partially due to HPV-induced immunogenicity. The development of novel therapeutic strategies that are specific for HPV-driven cancers requires tumor models that reflect as closely as possible the characteristics and complexity of human tumors and their response to treatment. Current HPV-positive cancer models lack one or more hallmarks of their human counterpart. This study presents the development of a new HPV16 oncoprotein-dependent tumor model in MHC-humanized mice, modeling the major biologic features of HPV-driven tumors and presenting HLA-A2-restricted HPV16 epitopes. Furthermore, this model was developed to be orthotopic (base of tongue). Thus, it also reflects the correct tumor microenvironment of HPV-driven HNSCC. The cancer cells are implanted in a manner that allows the exact control of the anatomical location of the developing tumor, thereby homogenizing tumor growth. In conclusion, the new model is suited to study HPV16-specific therapeutic vaccinations and other immunotherapies, as well as tumor-targeted interventions, such as surgery or radiotherapy, or a combination of all these modalities. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a head and neck squamous cell carcinoma |2 Other |
| 650 | _ | 7 | |a human papillomavirus |2 Other |
| 650 | _ | 7 | |a orthotopic tumor model |2 Other |
| 700 | 1 | _ | |a Zottnick, Samantha |0 P:(DE-He78)e03b110ee83e48c1f9c099c723c76e7e |b 1 |u dkfz |
| 700 | 1 | _ | |a Förster, Jonas |0 P:(DE-He78)1dfe5fa05989d8b5eeb8bd098e2f1c1f |b 2 |u dkfz |
| 700 | 1 | _ | |a Kruse, Sebastian |0 P:(DE-He78)2d912f097c2da0d6c989134e4e9aec18 |b 3 |
| 700 | 1 | _ | |a Yang, Ruwen |0 P:(DE-He78)9d9fc8bc93a08a610c9f4759bbf86bd7 |b 4 |
| 700 | 1 | _ | |a Wiethoff, Hendrik |0 P:(DE-He78)65980361d4934ac5be3a99a4b9cea356 |b 5 |u dkfz |
| 700 | 1 | _ | |a Bozza, Matthias |0 P:(DE-He78)3391c5ad790ea5359189d11f073fb103 |b 6 |
| 700 | 1 | _ | |a Hoppe-Seyler, Karin |0 P:(DE-He78)97468f1980416a4376b44e701d25f24b |b 7 |u dkfz |
| 700 | 1 | _ | |a Heikenwälder, Mathias |0 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |b 8 |u dkfz |
| 700 | 1 | _ | |a Harbottle, Richard P |0 P:(DE-He78)15dff5647002b4dcfe892b251cd14b62 |b 9 |u dkfz |
| 700 | 1 | _ | |a Michiels, Carine |0 0000-0002-9169-1294 |b 10 |
| 700 | 1 | _ | |a Riemer, Angelika |0 P:(DE-He78)3743a1b712edca2ffa829b7096d7037e |b 11 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.3390/pathogens12020188 |g Vol. 12, no. 2, p. 188 - |0 PERI:(DE-600)2695572-6 |n 2 |p 188 |t Pathogens |v 12 |y 2023 |x 2076-0817 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:274204 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)72642b84997c1dedbf3e62dd57dede80 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)e03b110ee83e48c1f9c099c723c76e7e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)1dfe5fa05989d8b5eeb8bd098e2f1c1f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)2d912f097c2da0d6c989134e4e9aec18 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)9d9fc8bc93a08a610c9f4759bbf86bd7 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)65980361d4934ac5be3a99a4b9cea356 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)3391c5ad790ea5359189d11f073fb103 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)97468f1980416a4376b44e701d25f24b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)15dff5647002b4dcfe892b251cd14b62 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)3743a1b712edca2ffa829b7096d7037e |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2022-08-24T11:01:46Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2022-11-17 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-17 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-17 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-17 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-17 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PATHOGENS : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2023-04-12T15:01:22Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2023-04-12T15:01:22Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2023-04-12T15:01:22Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-10-26 |
| 920 | 2 | _ | |0 I:(DE-He78)F130-20160331 |k F130 |l F130 Immuntherapie und -prävention |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F130-20160331 |k F130 |l F130 Immuntherapie und -prävention |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F030-20160331 |k F030 |l F030 Virale Transformationsmechanismen |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)F190-20160331 |k F190 |l F190 NWG Cell Plasticity and Epigenetic Remodeling |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)F160-20160331 |k F160 |l F160 DNA-Vektoren |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)F065-20160331 |k F065 |l F065 Molek. Therapie virusassozierter Tumore |x 4 |
| 920 | 1 | _ | |0 I:(DE-He78)F180-20160331 |k F180 |l F180 Chronische Entzündung und Krebs |x 5 |
| 920 | 0 | _ | |0 I:(DE-He78)F130-20160331 |k F130 |l F130 Immuntherapie und -prävention |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F130-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F030-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F190-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F160-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F065-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F180-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|